{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:43:15Z","timestamp":1792795395103,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00210-025-03916-3","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T04:26:22Z","timestamp":1741407982000},"page":"10939-10949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Toosendanin promotes prostate cancer cell apoptosis, ferroptosis and M1 polarization via USP39-mediated PLK1 deubiquitination"],"prefix":"10.1007","volume":"398","author":[{"given":"Siyao","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifeng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"7","key":"3916_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000513258","volume":"99","author":"V Achard","year":"2021","unstructured":"Achard V et al (2021) Localized and locally advanced prostate cancer: treatment options. Oncology 99(7):413\u2013421","journal-title":"Oncology"},{"issue":"5","key":"3916_CR2","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/cncr.32630","volume":"126","author":"B Bernard","year":"2020","unstructured":"Bernard B et al (2020) Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer 126(5):986\u2013993","journal-title":"Cancer"},{"issue":"16","key":"3916_CR3","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.2174\/0115701808291381240226094729","volume":"21","author":"L Bing","year":"2024","unstructured":"Bing L, Xiaoqiang L (2024) A linear and nonlinear QSAR analysis of benzimidazole derivative XY123 in prostate cancer treatment. Lett Drug Des Discov 21(16):3577\u20133589","journal-title":"Lett Drug Des Discov"},{"issue":"29","key":"3916_CR4","doi-asserted-by":"publisher","first-page":"22592","DOI":"10.1074\/jbc.M109.065003","volume":"285","author":"R Colnaghi","year":"2010","unstructured":"Colnaghi R, Wheatley SP (2010) Liaisons between survivin and Plk1 during cell division and cell death. J Biol Chem 285(29):22592\u201322604","journal-title":"J Biol Chem"},{"issue":"24","key":"3916_CR5","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/onc.2012.309","volume":"32","author":"A Deeraksa","year":"2013","unstructured":"Deeraksa A et al (2013) Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 32(24):2973\u20132983","journal-title":"Oncogene"},{"key":"3916_CR6","doi-asserted-by":"publisher","first-page":"110068","DOI":"10.1016\/j.cellsig.2021.110068","volume":"85","author":"X Dong","year":"2021","unstructured":"Dong X et al (2021) USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma. Cell Signal 85:110068","journal-title":"Cell Signal"},{"issue":"12","key":"3916_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4155\/fmc-2019-0084","volume":"11","author":"I Elsayed","year":"2019","unstructured":"Elsayed I, Wang X (2019) PLK1 inhibition in cancer therapy: potentials and challenges. Future Med Chem 11(12):1383\u20131386","journal-title":"Future Med Chem"},{"issue":"1","key":"3916_CR8","first-page":"127","volume":"13","author":"M Er-Rajy","year":"2023","unstructured":"Er-Rajy M et al (2023) 3D-QSAR studies, molecular docking, molecular dynamic simulation, and ADMET proprieties of novel pteridinone derivatives as PLK1 inhibitors for the treatment of prostate cancer. Life (Basel) 13(1):127","journal-title":"Life (Basel)"},{"issue":"13","key":"3916_CR9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1055\/s-0029-1240902","volume":"76","author":"Y He","year":"2010","unstructured":"He Y et al (2010) Toosendanin inhibits hepatocellular carcinoma cells by inducing mitochondria-dependent apoptosis. Planta Med 76(13):1447\u20131453","journal-title":"Planta Med"},{"issue":"12","key":"3916_CR10","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/pros.22683","volume":"73","author":"X Hou","year":"2013","unstructured":"Hou X et al (2013) Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate 73(12):1352\u20131363","journal-title":"Prostate"},{"key":"3916_CR11","doi-asserted-by":"publisher","first-page":"115541","DOI":"10.1016\/j.biopha.2023.115541","volume":"167","author":"M Hu","year":"2023","unstructured":"Hu M et al (2023) Therapeutic potential of toosendanin: novel applications of an old ascaris repellent as a drug candidate. Biomed Pharmacother 167:115541","journal-title":"Biomed Pharmacother"},{"issue":"16","key":"3916_CR12","doi-asserted-by":"publisher","first-page":"22016","DOI":"10.18632\/oncotarget.7882","volume":"7","author":"Y Huang","year":"2016","unstructured":"Huang Y et al (2016) Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation. Oncotarget 7(16):22016\u201322030","journal-title":"Oncotarget"},{"key":"3916_CR13","doi-asserted-by":"publisher","first-page":"114747","DOI":"10.1016\/j.bcp.2021.114747","volume":"193","author":"S Iliaki","year":"2021","unstructured":"Iliaki S, Beyaert R, Afonina IS (2021) Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochem Pharmacol 193:114747","journal-title":"Biochem Pharmacol"},{"key":"3916_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bcp.2018.03.022","volume":"152","author":"W Kai","year":"2018","unstructured":"Kai W et al (2018) Natural product toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor. Biochem Pharmacol 152:153\u2013164","journal-title":"Biochem Pharmacol"},{"issue":"16","key":"3916_CR15","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.7150\/ijbs.75063","volume":"18","author":"P Li","year":"2022","unstructured":"Li P et al (2022) ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner. Int J Biol Sci 18(16):6145\u20136162","journal-title":"Int J Biol Sci"},{"key":"3916_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.toxlet.2023.02.006","volume":"377","author":"Y Liang","year":"2023","unstructured":"Liang Y et al (2023) Toosendanin induced hepatotoxicity via triggering PERK-eIF2alpha-ATF4 mediated ferroptosis. Toxicol Lett 377:51\u201361","journal-title":"Toxicol Lett"},{"key":"3916_CR17","doi-asserted-by":"publisher","first-page":"1032579","DOI":"10.3389\/fonc.2022.1032579","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y et al (2022) DNAAF5 promotes hepatocellular carcinoma malignant progression by recruiting USP39 to improve PFKL protein stability. Front Oncol 12:1032579","journal-title":"Front Oncol"},{"issue":"5","key":"3916_CR18","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.3892\/mmr.2014.3139","volume":"11","author":"W Lu","year":"2015","unstructured":"Lu W, Du S, Wang J (2015) Berberine inhibits the proliferation of prostate cancer cells and induces G(0)\/G(1) or G(2)\/M phase arrest at different concentrations. Mol Med Rep 11(5):3920\u20133924","journal-title":"Mol Med Rep"},{"issue":"5","key":"3916_CR19","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD et al (2022) Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 72(5):409\u2013436","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3916_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bbrc.2017.08.170","volume":"493","author":"Z Pei","year":"2017","unstructured":"Pei Z, Fu W, Wang G (2017) A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt\/mTOR signaling. Biochem Biophys Res Commun 493(1):455\u2013460","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"3916_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS (2018) Metastatic prostate cancer. N Engl J Med 378(7):645\u2013657","journal-title":"N Engl J Med"},{"issue":"3","key":"3916_CR22","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3892\/mmr.2020.11263","volume":"22","author":"S Shao","year":"2020","unstructured":"Shao S et al (2020) Toosendanin induces apoptosis of MKN-45 human gastric cancer cells partly through miR-23a-3p-mediated downregulation of BCL2. Mol Med Rep 22(3):1793\u20131802","journal-title":"Mol Med Rep"},{"issue":"1","key":"3916_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2007.02.002","volume":"82","author":"YL Shi","year":"2007","unstructured":"Shi YL, Li MF (2007) Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Prog Neurobiol 82(1):1\u201310","journal-title":"Prog Neurobiol"},{"issue":"1","key":"3916_CR24","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"key":"3916_CR25","doi-asserted-by":"publisher","first-page":"109745","DOI":"10.1016\/j.intimp.2023.109745","volume":"116","author":"T Tan","year":"2023","unstructured":"Tan T et al (2023) Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway. Int Immunopharmacol 116:109745","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"3916_CR26","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/biom10111536","volume":"10","author":"D Termini","year":"2020","unstructured":"Termini D et al (2020) Curcumin against prostate cancer: current evidence. Biomolecules 10(11):1536","journal-title":"Biomolecules"},{"issue":"7","key":"3916_CR27","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3390\/ijms22073753","volume":"22","author":"MT Vietri","year":"2021","unstructured":"Vietri MT et al (2021) Hereditary prostate cancer: genes related, target therapy and prevention. Int J Mol Sci 22(7):3753","journal-title":"Int J Mol Sci"},{"key":"3916_CR28","doi-asserted-by":"publisher","first-page":"154571","DOI":"10.1016\/j.phymed.2022.154571","volume":"109","author":"G Wang","year":"2023","unstructured":"Wang G et al (2023a) Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195\/ERK\/beta-catenin pathway. Phytomedicine 109:154571","journal-title":"Phytomedicine"},{"issue":"1","key":"3916_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41419-023-05593-7","volume":"14","author":"W Wang","year":"2023","unstructured":"Wang W et al (2023b) USP39 stabilizes beta-catenin by deubiquitination and suppressing E3 ligase TRIM26 pre-mRNA maturation to promote HCC progression. Cell Death Dis 14(1):63","journal-title":"Cell Death Dis"},{"key":"3916_CR30","doi-asserted-by":"publisher","first-page":"101713","DOI":"10.1016\/j.tranon.2023.101713","volume":"34","author":"Y Xiao","year":"2023","unstructured":"Xiao Y et al (2023) USP39-mediated deubiquitination of Cyclin B1 promotes tumor cell proliferation and glioma progression. Transl Oncol 34:101713","journal-title":"Transl Oncol"},{"issue":"2","key":"3916_CR31","doi-asserted-by":"publisher","first-page":"152786","DOI":"10.1016\/j.prp.2019.152786","volume":"216","author":"L Yan","year":"2020","unstructured":"Yan L et al (2020) miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells. Pathol Res Pract 216(2):152786","journal-title":"Pathol Res Pract"},{"issue":"12","key":"3916_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s11418-018-1227-5","volume":"16","author":"Q Zhang","year":"2018","unstructured":"Zhang Q et al (2018) New limonoids isolated from the bark of Melia toosendan. Chin J Nat Med 16(12):946\u2013950","journal-title":"Chin J Nat Med"},{"issue":"3","key":"3916_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/10286020.2018.1451516","volume":"21","author":"S Zhang","year":"2019","unstructured":"Zhang S et al (2019) Anti-cancer effect of toosendanin and its underlying mechanisms. J Asian Nat Prod Res 21(3):270\u2013283","journal-title":"J Asian Nat Prod Res"},{"issue":"5","key":"3916_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/ddr.21951","volume":"83","author":"M Zhang","year":"2022","unstructured":"Zhang M et al (2022a) Toosendanin inhibits colorectal cancer cell growth through the Hedgehog pathway by targeting Shh. Drug Dev Res 83(5):1201\u20131211","journal-title":"Drug Dev Res"},{"issue":"8","key":"3916_CR35","first-page":"3644","volume":"12","author":"Z Zhang","year":"2022","unstructured":"Zhang Z et al (2022b) USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1. Am J Cancer Res 12(8):3644\u20133661","journal-title":"Am J Cancer Res"},{"key":"3916_CR36","doi-asserted-by":"publisher","first-page":"109739","DOI":"10.1016\/j.cbi.2021.109739","volume":"351","author":"J Zhang","year":"2022","unstructured":"Zhang J et al (2022c) Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy. Chem Biol Interact 351:109739","journal-title":"Chem Biol Interact"},{"key":"3916_CR37","doi-asserted-by":"publisher","first-page":"115711","DOI":"10.1016\/j.biopha.2023.115711","volume":"168","author":"M Zhao","year":"2023","unstructured":"Zhao M et al (2023) PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway\/ferroptosis. Biomed Pharmacother 168:115711","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"3916_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41419-023-06210-3","volume":"14","author":"J Zheng","year":"2023","unstructured":"Zheng J et al (2023) USP39 promotes hepatocellular carcinogenesis through regulating alternative splicing in cooperation with SRSF6\/HNRNPC. Cell Death Dis 14(10):670","journal-title":"Cell Death Dis"},{"issue":"12","key":"3916_CR39","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s10529-020-02984-0","volume":"42","author":"M Zong","year":"2020","unstructured":"Zong M et al (2020) LncRNA TUG1 promotes esophageal cancer development through regulating PLK1 expression by sponging miR-1294. Biotechnol Lett 42(12):2537\u20132549","journal-title":"Biotechnol Lett"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03916-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03916-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03916-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:11:39Z","timestamp":1757142699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03916-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3916"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03916-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consents were obtained from all participants and this study was permitted by the Ethics Committee of Jiangxi Province Hospital of Integrated Chinese and Western Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents were obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}